Localized Immunotherapy by Direct Injection Treats Solid Tumors and Activates the Immune System with Lew Bender Intensity Therapeutics

Lew Bender, Founder and CEO of Intensity Therapeutics, has developed a novel approach to treating solid tumors through direct intratumoral injection of existing chemotherapy drugs. The company uses a proprietary formulation containing a special molecule that makes water-based drugs soluble in fatty tissue, allowing cisplatin and vinblastine to penetrate tumor cells effectively. Beyond direct killing of cancer cells, the approach triggers an immunological response that trains the immune system to recognize and attack cancer cells throughout the body, including metastatic tumors that were not directly injected. Lew explains, "We're injecting directly into the tumors, and we have identified a formulation that allows for water-based drugs to become soluble in fat and water. Effectively, a tumor is fat and water. And while it has been tried before to inject water into fat, I helped to develop a chemistry that allows for water-based products to be absorbed by fatty tissue like tumors." "We are injecting our formulation, which is a special molecule called SHAO, that makes things soluble in fat and water, and two very well-known potent anti-cancer agents, cisplatin and vinblastine, that are able to kill cancers when they get into the cancer cells. So we dose based on the size of the tumor, check into the tumors, and the tumors in an immunological way. So what does that mean? It means that as the tumor cells die, they create chemicals that allow for the influx and recognition of the immune cells that this is not a good entity to be in the body." "We are killing the cancer with the drug, but at the same time training the immune system on the tumors so that the immune system can recognize the cancer as not self and attack the cancer in a more precise way." #IntensityTherapeutics $INTS  #CancerResearch #Oncology #Biotech #CancerCare  #ClinicalTrials #BreastCancer #TargetedOncology #IntratumoralInjection #OncologyInnovation #ImmunoOncology #IntratumoralTherapy #SolidTumors #TNBC #Sarcoma #HealthcareProfessionals intensitytherapeutics.com Download the transcript here